Redesigning TRACER trial after TRITON

International Journal of Cardiology

Volumn 197, Issue , 2015, Pages 44-47

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trials; Outcomes; Prasugrel; Trial design; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; PLACEBO; PRASUGREL; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STUDY DESIGN; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG SCREENING; HEMORRHAGE; METHODOLOGY; NEOPLASMS;

ACUTE CORONARY SYNDROME; ASPIRIN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; LACTONES; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PYRIDINES; RESEARCH DESIGN; TICLOPIDINE;

EID: 84938511890     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.06.020     Document Type: Editorial

References (11)

1. H.C. Diener, R. Sacco, S. Yusuf, Steering Committee, and PRoFESSStudy Group Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS) Cerebrovasc. Dis. 23 2007 368 380
2. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, M. Kaste, D. Leys, J. Matias-Guiu, H.J. Rupprecht, and MATCH investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
3. R.L. Sacco, H.C. Diener, S. Yusuf, D. Cotton, S. Ounpuu, W.A. Lawton, Y. Palesch, R.H. Martin, G.W. Albers, P. Bath, N. Bornstein, B.P. Chan, S.T. Chen, L. Cunha, B. Dahlöf, J. De Keyser, G.A. Donnan, C. Estol, P. Gorelick, V. Gu, K. Hermansson, L. Hilbrich, M. Kaste, C. Lu, T. Machnig, P. Pais, R. Roberts, V. Skvortsova, P. Teal, D. Toni, C. Vandermaelen, T. Voigt, M. Weber, B.W. Yoon, and PRoFESS Study Group Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N. Engl. J. Med. 359 2008 1238 1251
4. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, F. Van de Werf, H.D. White, P.E. Aylward, L. Wallentin, E. Chen, Y. Lokhnygina, J. Pei, S. Leonardi, T.L. Rorick, A.M. Kilian, L.H. Jennings, G. Ambrosio, C. Bode, A. Cequier, J.H. Cornel, R. Diaz, A. Erkan, K. Huber, M.P. Hudson, L. Jiang, J.W. Jukema, B.S. Lewis, A.M. Lincoff, G. Montalescot, J.C. Nicolau, H. Ogawa, M. Pfisterer, J.C. Prieto, W. Ruzyllo, P.R. Sinnaeve, R.F. Storey, M. Valgimigli, D.J. Whellan, P. Widimsky, J. Strony, R.A. Harrington, K.W. Mahaffey, and the TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J. Med. 366 2012 20 33
5. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman, and the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
6. Prasugrel Secondary Review Available for download at http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm Assessed May 12, 2015
7. Food and Drug Administration Briefing Document, February 3, 2009 Meeting of FDA Cardiovascular and Renal Drugs Advisory Committee on Prasugrel Available for download at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm181185.pdf Assessed May 12, 2015
8. G. Montalescot, S.D. Wiviott, E. Braunwald, S.A. Murphy, C.M. Gibson, C.H. McCabe, E.M. Antman, and TRITON-TIMI 38 investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
9. NDA 294-886 Cross-discipline Team Leader Review on Vorapaxar April 18th, 2014 Available for download at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/204886Orig1s000SumR.pdf Assessed May 15, 2015
10. D.P. Chew, D.L. Bhatt, S. Sapp, and E.J. Topol Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials Circulation 103 2001 201 206
11. V. Serebruany, and D. Atar Prasugrel: the real-life perspective Circ. Cardiovasc. Qual. Outcomes 6 2013 253 254